Iovance Biotherapeutics Inc. (2LB)
Munich
9.77
+0.32 (+3.39%)
Closed
Sep 29, 2026
Day's Range
9.599.77
52 wk Range
1.609.77
Financial Statements - 2LB - Iovance Biotherapeutics Inc.
Revenue
263.50M▲ 60.6%
Net Income
-390.97M▼ 5.1%Net Margin -148.4%
EBITDA
-345.74M▲ 1.7%
Free Cash Flow
-336.24M▲ 7.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 263.50M | 164.07M | 1.18M | 0 | 0 | 0 |
| Cost of Goods | 173.18M | 123.99M | 10.75M | 0 | 0 | - |
| Gross Profit | 90.31M | 40.07M | -9.56M | 0 | 0 | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -398.21M | -395.27M | -460.55M | -398.87M | -342.70M | -261.93M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -5.14M | - | - | - | - | - |
| Pre Tax Income | -393.04M | -375M | -447.51M | -395.89M | -342.25M | -259.58M |
| Income Tax | -2.07M | -2.82M | -3.47M | 0 | 0 | - |
| Net Income | -390.97M | -372.17M | -444.03M | -395.89M | -342.25M | -259.58M |
| EPS Basic | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 |
| EPS Diluted | -1.094119 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 |
| Basic Shares Outstanding | 357.34M | 289.87M | 246.44M | 165.74M | 159.65M | 143.93M |
| Diluted Shares Outstanding | 357.34M | 289.87M | 246.44M | 165.74M | 159.65M | 143.93M |
| Ebit | -398.21M | -395.27M | -460.55M | -398.87M | -342.70M | -261.93M |
| Ebitda | -345.74M | -351.67M | -427.43M | -377.74M | -328.72M | -253.22M |
| Net Income Continuous Operations | -390.97M | -372.17M | -444.03M | -395.89M | -342.25M | -259.58M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
